Vedolizumab

What is Vedolizumab

Vedolizumab is a monoclonal antibody that is a specific integrin receptor antagonist. It is used for the treatment of moderately to severely active ulcerative colitis and Crohn’s disease in adult patients.

Treatment with vedolizumab is appropriate for patients who have failed to fully respond to tumor necrosis factor (TNF) blocker, immunomodulator, or corticosteroid therapy or who are intolerant to or demonstrated dependence on corticosteroids.

Brand Name

Entyvio

Indications

  • Crohn’s disease
  • ulcerative colitis

For moderately to severely active ulcerative colitis to reduce signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapy

Side Effects

  1. anaphylactoid reactions
  2. antibody formation
  3. arthralgia
  4. back pain
  5. bronchospasm
  6. cough
  7. dyspnea
  8. elevated hepatic enzymes
  9. fatigue
  10. fever
  11. flushing
  12. headache
  13. hepatic failure
  14. hepatitis
  15. infection
  16. influenza
  17. jaundice
  18. leukoencephalopathy
  19. musculoskeletal pain
  20. nausea
  21. new primary malignancy
  22. pharyngitis
  23. pruritus
  24. rash
  25. sinusitis

Monitoring Parameters

  • LFTs

Contraindications

  • breast-feeding
  • hepatic disease
  • human anti-chimeric antibody (HACA)
  • immunosuppression
  • infants
  • infection
  • jaundice
  • neonates
  • pregnancy
  • progressive multifocal leukoencephalopathy
  • sepsis
  • tuberculosis
  • vaccination

Interactions

  • Adalimumab
  • Certolizumab pegol
  • Etanercept
  • Golimumab
  • Infliximab
  • Live Vaccines
  • Natalizumab
  • Tumor Necrosis Factor modifiers
15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top